abstract |
Kind Code: A1 The present invention is selected from among fractured fractures, false internode fractures, dispersive bones, surgically formed bone defects, surgically treated bone defects, or bone trauma or diseased bone defects. Providing a method for treating a human having a bone gap defect. An effective amount of a sclerostin inhibitor (eg, an anti-sclerostin antibody) is applied to a subject, optionally from about 1 to about 50 mg / kg, preferably over a treatment period lasting at least 20 weeks, preferably about 28 weeks, preferably , 30 mg / kg weekly dosage. A method wherein the sclerostin inhibitor is administered once a week, once every two weeks, or twice a week during the treatment period. [Selection figure] None |